Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials

AXL Inhibition Specialist BerGenBio's $24m Private Placement To Fund Pipeline, Trials

BerGenBio CEO says the Norwegian biotech aims, either alone or in partnership, to develop and commercialize its lead asset through to marketing approval in a variety of cancers.

Financing ImmunoOncology Companies
Advertisement

Clinical Trials

Set Alert for Clinical Trials

Latest From Clinical Trials

Experts Challenge GSK Triple Inhaled COPD Therapy Claims

While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.

Clinical Trials Research & Development

With Back-To-Back FDA Holds, Solid Hopes To Regain Footing For Duchenne Candidate

The US FDA wants more information on the first patient given SGT-001, who was hospitalized with a reduced platelet count after dosing. Solid says the patient is doing well and hopes to reply to the FDA's concerns within weeks.
Research & Development Clinical Trials

In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts

Bristol's stock price dipped after the AACR meeting, where pivotal lung cancer data for Opdivo/Yervoy disappointed relative to Merck's Keytruda/chemo combo, but Bristol still has many immuno-oncology irons in the fire in other indications and expressed confidence in its strategy.

Clinical Trials ImmunoOncology

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.

Clinical Trials Cancer

ImmuPharma Puts On Very Brave Face After Lupus Drug Flop

Shares in the UK biotech have fallen through the floor following a failed Phase III trial of Lupuzor but ImmuPharma remains surprisingly upbeat about the lupus drug's prospects.

Immune Disorders Clinical Trials

Hanmi Halts Olmutinib Development After Alliances Crumble

Hanmi is set to focus on other assets in its innovative drug pipeline after it ends development of novel lung cancer drug olmutinib amid ZAI Lab’s recent cancellation of a licensing agreement with the South Korean pharma.

Research & Development Clinical Trials
See All
UsernamePublicRestriction

Register